Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
about
Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of SubgroupsAssessing bleeding risk in patients taking anticoagulantsStroke prevention in atrial fibrillation: latest clinical trials and guidelinesEfficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulationNon-Vitamin K Oral Anticoagulants in Stroke Patients: Practical IssuesThe case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefit-risk ratioHow to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillationStroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulantsDabigatran-Associated Intracranial Hemorrhage: Literature Review and Institutional ExperienceRisk of Fatal Bleeding in Episodes of Major Bleeding with New Oral Anticoagulants and Vitamin K Antagonists: A Systematic Review and Meta-AnalysisPractical and clinical considerations in assessing patients with atrial fibrillation for switching to non-vitamin K antagonist oral anticoagulants in primary careDirect Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and SimilaritiesNovel Anticoagulants in Atrial Fibrillation: Monitoring, Reversal and Perioperative ManagementAntithrombotic management of atrial fibrillation in the elderlySafety of new oral anticoagulant drugs: a perspectiveAnticoagulation drug therapy: a reviewCare transitions in anticoagulation management for patients with atrial fibrillation: an emphasis on safetyNo influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.Minimizing bleeding risk in patients receiving direct oral anticoagulants for stroke preventionAtrial fibrillation management in older heart failure patients: a complex clinical problemDirect oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced ageEfficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-AnalysisDRUG-DRUG INTERACTION PROFILES OF MEDICATION REGIMENS EXTRACTED FROM A DE-IDENTIFIED ELECTRONIC MEDICAL RECORDS SYSTEMCerebral microbleeds on magnetic resonance imaging and anticoagulant-associated intracerebral hemorrhage riskDirect anticoagulant drugs to overcome limitations of vitamin K antagonists. A critical appraisal of data in atrial fibrillation patients.Use of Direct-Acting Oral Anticoagulants in Nonagenarians: A Call for More Data.Real Data on Effectiveness, Tolerability and Safety of New Oral Anticoagulant Agents: Focus on Dabigatran.Traumatic fatal cerebral hemorrhage in an old patient with a history of multiple sclerosis under dabigatran: a case report and review of the literatureHemorrhagic complications associated with dabigatran use.Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach.Translational insights into traumatic brain injury occurring during dabigatran or warfarin anticoagulation.Benefits of once-daily dosing with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.Hemostasis and alterations of the central nervous systemFrequency and predictors of bleeding complications associated with anti-coagulant therapy using dabigatran in Japanese patients with atrial fibrillationPreventive strategies against bleeding due to nonvitamin K antagonist oral anticoagulants.Trials of novel oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial.Anticoagulation in Patients Aged ≥75 years with Atrial Fibrillation: Role of Novel Oral Anticoagulants.Characteristics affecting oral anticoagulant therapy choice among patients with non-valvular atrial fibrillation: a retrospective claims analysis.
P2860
Q21284803-E8C93767-6D56-4DE6-B551-35B4781EE530Q24619070-F33BA5C6-7228-4411-B2C4-EC20EB4C0DE3Q24628390-BDF143A8-CB01-42DD-BB45-DF1379E822C8Q26749141-A9F2F6EA-A979-4A0F-98E3-A5E32AB40132Q26750767-14EECD98-D7ED-47B9-A269-D1943DE09DC9Q26776239-7A05B4A5-DB41-4F8C-8743-0BE4AFED7878Q26776413-D17AC746-8F3C-4F77-8417-7CA181BCE57BQ26781181-ED73F92C-DC05-458F-8A60-E319685AA325Q26783457-BC4D4474-0420-4EA2-804A-5901458195D8Q26783473-B1AA7D4D-7947-442E-A70F-4544BA98BF16Q26785480-C124BAD8-775C-40F7-BAE0-34559DF9F2E5Q26787046-D62F2D1D-10B5-480B-88D0-286FD99B0E4FQ26801895-30A9B3E6-4A99-4E50-92A6-3E3EF07C85F4Q26827113-0E92FA68-9448-46BB-862E-F37BFBA15058Q27016072-F2B16672-10EC-4E4E-BEC0-047E80D958A2Q27021871-C532D213-6E68-4796-B9D1-25244E831D78Q27025527-EAC9960A-1505-4833-8287-E029C3CC69D3Q27334041-4E815A16-8C26-4D97-A335-9CF38F77E8F9Q27341873-590A2967-8E95-4707-A4E8-1233658BDA24Q28069809-ECAAFFF5-8309-48E9-9858-F20BB6103BB7Q28076170-6D4C3290-83DC-4F88-A10F-C93977DC279AQ28079930-6795CBF4-3E6E-4A69-A54D-2A1D98BBC2ACQ28085676-205EC2A6-DAC3-4AD3-B727-17A4A28CE6BAQ28828695-0B923B8E-C865-47F7-8FDE-20BE20DEF993Q30570918-CCD92532-21C0-4BBD-A9D7-F33984148172Q30595943-E02D2DDF-2449-43C3-A5EB-8965840F74E7Q31066944-510B33A6-87DF-4633-BF40-646B5E399343Q31098679-9B05AFD0-A810-488B-87F7-A5683DDFAC85Q33165278-1BBBDD65-7C20-46D9-BCAF-5BAD98078EEEQ33403265-BC24A6E2-9B2A-44DC-A582-F518EC77EE7FQ33427274-2C13B6AB-0D2C-457D-905A-5877594D3234Q33581189-841D9FE0-1DA2-40D4-8B8C-11D2DA7E6364Q33646770-AFB5BB8D-067B-416F-841E-F2744DAE4FCBQ33842161-54691721-C53A-4C69-A9A3-10AB59E63A89Q33847039-BA6E9A06-C362-4F2E-B7EF-DC308CE53652Q33854667-03E1FEDB-B5C9-452E-8945-43E571B45C11Q33911981-6A92D2A5-7DF4-4A35-836A-C28AFF1D22A8Q33924260-FE4178B9-C31E-41E3-9043-4EA623D587E5Q33936087-E337F34E-148B-4EAE-B64B-32E254769934Q33957383-25B4C2D5-1DB2-4F32-A28E-10B1909B3CAC
P2860
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Risk of bleeding with 2 doses ...... agulant therapy (RE-LY) trial.
@en
type
label
Risk of bleeding with 2 doses ...... agulant therapy (RE-LY) trial.
@en
prefLabel
Risk of bleeding with 2 doses ...... agulant therapy (RE-LY) trial.
@en
P2093
P50
P921
P1433
P1476
Risk of bleeding with 2 doses ...... agulant therapy (RE-LY) trial.
@en
P2093
Jeanne Varrone
Jeff S Healey
Jonas Oldgren
Kurt Huber
Marco Alings
Maria Grazia Franzosi
Mike Ezekowitz
Paul Reilly
Scott Kaatz
P304
P356
10.1161/CIRCULATIONAHA.110.004747
P407
P577
2011-05-16T00:00:00Z